WITHUS PHARMACEUTICAL Co (330350) Fair Value & Analysis
Healthcare · KR · Market cap 87.9B KRW
Fair value as of: Jun 24, 2026
Analysis
WITHUS PHARMACEUTICAL Co (330350) currently trades at 7,510 KRW, while our model-based Fair Value estimate is 5,961 KRW — implying the stock looks roughly 20.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products. The company was previously known as Withers Medipharm Co. , Ltd. and changed its name to WITHUS PHARMACEUTICAL Co.,LTD. in October 2007. WITHUS PHARMACEUTICAL Co.,LTD. was founded in 2004 and is headquartered in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is WITHUS PHARMACEUTICAL Co (330350) undervalued?
What is the fair value of 330350?
What is the quality score of 330350?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.